Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 626 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Otsuka Phase III ADPKD trial meets primary endpoint

The placebo-controlled, parallel-arm study demonstrated nearly 50% reduction in the change of total kidney volume among autosomal dominant polycystic kidney disease (ADPKD) patients as compared to placebo over

Sweden funds new anti-malaria therapy

Sevuparin is an adjunctive therapy to anti-parasite medicines to prevent the infected red blood cells from obstructing blood vessels to reduce mortality. The grant from Vinnova will be

Valeant Q3 net income declines

Total revenues for third quarter of 2012 were $884.14m compared to $600.58m for the third quarter of 2011. The company reported a net loss of $26.88m, or $0.09